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Anti-rabies virus immunoglobulin combined with rabies vaccine protects humans from lethal rabies infec-
tions. For cost and safety reasons, replacement of the human or equine polyclonal immunoglobulin is advo-
cated, and the use of rabies virus-specific monoclonal antibodies (MAbs) is recommended. We produced two
previously described potent rabies virus-neutralizing human MAbs, CR57 and CRJB, in human PER.C6 cells.
The two MAbs competed for binding to rabies virus glycoprotein. Using CR57 and a set of 15-mer overlapping
peptides covering the glycoprotein ectodomain, a neutralization domain was identified between amino acids
(aa) 218 and 240. The minimal binding region was identified as KLCGVL (aa 226 to 231), with key residues
K-CGV- identified by alanine replacement scanning. The critical binding region of this novel nonconforma-
tional rabies virus epitope is highly conserved within rabies viruses of genotype 1. Subsequently, we generated
six rabies virus variants escaping neutralization by CR57 and six variants escaping CRJB. The CR57 escape
mutants were only partially covered by CRJB, and all CRJB-resistant variants completely escaped neutral-
ization by CR57. Without exception, the CR57-resistant variants showed a mutation at key residues within the
defined minimal binding region, while the CRJB escape viruses showed a single mutation distant from the
CR57 epitope (N182D) combined with mutations in the CR57 epitope. The competition between CR57 and
CRJB, the in vitro escape profile, and the apparent overlap between the recognized epitopes argues against
including both CR57 and CRJB in a MAb cocktail aimed at replacing classical immunoglobulin preparations.
Lethal rabies is prevented by postexposure prophylaxis
(PEP) through the combined administration of a rabies virus
vaccine and rabies virus immunoglobulin (RIG). Two types of
RIG are used: human RIG (HRIG) and equine RIG (ERIG),
both derived from pooled sera of human donors or horses
vaccinated against rabies virus, respectively. The need to re-
place these hyperimmune serum preparations is widely recog-
nized (1), and MAbs that neutralize rabies virus offer the
opportunity to do so.
Mouse monoclonal antibodies (MAbs) as well as human
MAbs have been shown to protect rodents from a lethal rabies
virus challenge (8, 11, 14, 15, 20, 25, 26). One of the most
potent of the human antibodies neutralizing a variety of rabies
virus strains was described by Dietzschold et al. (8). This hu-
man antibody (MAb57) was subsequently included in a cock-
tail of three human antibodies, SOJA, SOJB, and SO57, that
was shown to be as effective as HRIG in protection of mice
from a lethal dose of rabies virus (25).
We considered two criteria to be of crucial importance for
the inclusion of human MAbs into a cocktail aimed at effec-
tively blocking rabies virus infections acquired from wildlife
animals. Firstly, the MAbs should target distinct, nonoverlap-
ping epitopes and preferably should not compete for binding to
rabies virus glycoprotein. Secondly, in vitro-generated anti-
body-resistant rabies virus variants selected using one antibody
should be neutralized by the nonselecting other antibody in the
cocktail (and vice versa), thus addressing the issue of natural
variation among rabies virus field isolates.
In the present study, the variable heavy- and light-chain
coding regions of the SOJA, SOJB, and SO57 antibody genes
were synthesized, introduced into a single human immuno-
globulin G1 (IgG1) expression vector, and expressed in human
PER.C6 cells (17). This yielded the antibodies CR57, CRJB,
and CRJA. The potency of CR57 was significantly greater than
that of CRJB, while the potency of CRJA was poor and there-
fore was not included in further studies. Binding analyses re-
vealed that CR57 and CRJB compete for binding to rabies
virus glycoprotein. Using CR57, we identified a novel linear
epitope on the rabies virus glycoprotein by scanning the com-
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plete extracellular domain for peptide recognition using Pep-
scan technology (13, 28). The key residues of the epitope were
identified next. Subsequently, rabies virus variants were gen-
erated that escaped neutralization by either CR57 or CRJB.
The glycoprotein gene of these antibody-resistant variants was
sequenced to identify critical amino acid residues involved in
the binding region of each of these antibodies. Variant resi-
dues were introduced in peptides mimicking the epitope and
were tested for loss of MAb binding. An updated antigenic
map of the rabies virus glycoprotein is included that incorpo-
rates the novel CR57 epitope.
MATERIALS AND METHODS
Cells. Mouse neuroblastoma (NA) cells were grown at 37°C and 5% CO2 in
RPMI 1640 (Gibco) supplemented with 10% heat-inactivated fetal bovine serum
(FBS). BSR cells (a subclone of baby hamster kidney cells) were grown at 37°C
and 5% CO2 in Dulbecco’s modified Eagle medium (DMEM; Gibco) supple-
mented with 10% FBS. PER.C6 cells (12) were grown at 37°C and 10% CO2 in
DMEM (Gibco) supplemented with 10% FBS and 10 mM MgCl2.
Antibodies. The heavy and light chains of the antibodies CR57, CRJB, and
CRJA, as described previously (25), were cloned indirectly into the pcDNA3002
vector (17) via shuttle vectors containing the constant domains of the IgG1 heavy
chain, the kappa light chain, and the lambda light chain, respectively. Antibodies
CR57, CRJB, and CRJA were expressed in PER.C6 cells and purified by protein
A chromatography. Antibodies were buffered with phosphate-buffered saline
(PBS) (Gibco), filter sterilized, and stored at 20°C. Biotinylation of antibodies
was performed using EZ-link Sulfo NHS-SS-biotin (Pierce) according to stan-
dard laboratory procedures.
Virus. Monolayers of BSR cells were infected with CVS-11 (challenge virus
standard) at a multiplicity of infection (MOI) of 0.1 for 1 h at 37°C and 5% CO2.
The virus inoculum was then removed, fresh medium was added to the cells, and
the mixture was incubated for 72 h at 34°C and 5% CO2. The culture superna-
tants were collected and stored at 80°C until further use.
RFFIT. Modified rapid fluorescent focus inhibition neutralization test (RFFIT)
neutralization assays were performed as described previously (8).
Competition experiments. Enzyme-linked immunosorbent assay (ELISA)
plates coated with purified rabies virus glycoprotein (ERA strain; 1 g/ml) were
incubated with 50 g of unlabeled anti-rabies virus glycoprotein IgG/ml for 1 h
at room temperature. Fifty microliters of biotinylated anti-rabies virus glyco-
protein IgG (2.5 g/ml) was then added to each well, incubated for 5 min at room
temperature, and immediately washed five times with 100 l of PBS–0.05%
Tween-20. Subsequently, wells were incubated for 1 h at room temperature with
50 l of a 1:2,000 dilution of streptavidin-horseradish peroxidase (HRP) (Becton
Dickinson), washed, and developed by addition of 100 l of OPD reagent
(Sigma). The reaction was stopped by adding 50 l of 1 M H2SO4 before
measuring the optical density at 492 nm (OD492). Alternatively, competition
experiments were performed using PER.C6 cells expressing rabies virus glyco-
protein. Cells were transiently transfected using Fugene (Gibco) with a plasmid
encoding the full-length rabies virus glycoprotein of the ERA strain. Two days
after transfection, the cells were harvested and used in the competition assay.
Cells were then incubated with saturating amounts of unlabeled antibody at 4°C
before washing and addition of 2.5 g of biotinylated antibodies/ml. Bound
biotinylated antibodies were visualized after 5 min with streptavidin-phyco-
erythrin (PE) conjugate (Becton Dickinson), and samples were analyzed by flow
cytometry.
Generation of escape viruses. Serial dilutions (0.5 ml) of CVS-11 ranging from
101 to 108 focus-forming units (FFU)/ml were incubated with a constant
amount (4 IU/ml) of antibody CR57 or CRJB (0.5 ml) for 1 h at 37°C and 5%
CO2. The mixtures were added to 2-day-old NA cells or BSR cells in 12-well
plates. After 3 days of incubation in the presence of a 4-IU/ml concentration of
either human monoclonal antibody CR57 or CRJB, medium (1 ml) containing
potential escape viruses was harvested and stored at 4°C until further use.
Subsequently the cells were acetone fixed for 20 min at 4°C and stained overnight
at 37°C and 5% CO2 with an anti-rabies virus N-fluorescein isothiocyanate
(FITC) antibody conjugate (Centocor). The number of foci per well was scored
by immunofluorescence, and supernatants from wells infected with the lowest
dilution of virus which produced one to six fluorescent foci were chosen for
escape virus amplification. The number of foci for each escape virus differed,
ranging from one to six foci/well. All E57 escape viruses were generated from a
single focus, except E57B1 (three foci). EJB viruses were isolated from one focus
(EJB3F), three foci (EJB2B), four foci (EJB2C), five foci (EJB2E, EJB2F), or six
foci (EJB2D), respectively.
Determination of the NI. Escape virus (2 ml) was incubated at 106 FFU/ml
with either CR57 or CRJB (4 IU/ml) for 1 h at 37°C and 5% CO2. Monolayers
of 2-day-old NA cells in T25 flasks were washed with PBS (Gibco); the virus-
MAb mixture was added to the cells and incubated for 1 h at 37°C and 5% CO2.
After virus attachment, the medium containing virus-antibody mix was removed,
and cells were washed twice with medium and incubated for 48 h at 34°C and 5%
CO2 in medium supplemented with 4 IU of their respective antibody/ml. Har-
vested medium was used to titrate the virus on NA cells to determine the
focus-forming units per milliliter. The neutralization index (NI) was calculated
with the formula NI  log[FFU/ml  IgG]  log[FFU/ml  IgG]. An index
lower than 2.5 was considered evidence of escape from neutralization by the
antibody.
cDNA sequencing. Amplified virus stocks were used to inoculate a monolayer
of NA cells (MOI  1.0). Two days postinfection the cells were harvested, and
total RNA was isolated using a QIAGEN RNeasy mini kit according to the
manufacturer’s instructions. Subsequently, reverse transcription-PCR (RT-PCR)
was performed using rabies virus-specific primers and the One-Step SuperScript
RT-PCR with Platinum Taq DNA polymerase (Invitrogen) according to the
manufacturer’s recommendations. cDNA was then sequenced by standard pro-
cedures.
Epitope mapping. The 15-mer linear overlapping peptides (overlap by 14
amino acids) were synthesized spanning the extracellular domain of the G pro-
tein of the rabies virus strain ERA (amino acids [aa] 20 to 458; GenBank
accession no. J02293) and screened using credit card format mini-PEPSCAN
cards as described previously (28). Additionally, 8-mer peptides were synthesized
that overlapped by 7 amino acids spanning only the region reactive with CR57.
Binding of the antibodies to each linear peptide was tested in a PEPSCAN-based
ELISA. The 455-well credit card format polypropylene cards, containing the
covalently linked peptides, were incubated with the human anti-rabies virus
antibody (10 g/ml; diluted in blocking solution, which contains 5% [vol/vol]
horse serum and 5% [wt/vol] ovalbumin) (4°C, overnight). After washing, the
peptides were incubated with anti-human antibody peroxidase at a dilution of
1/1,000 for 1 h at 25°C. The peptides were then washed, and the peroxidase
substrate 2,2-azino-di-3-ethylbenzthiazoline sulfonate (ABTS) and 2 l of 3%
H2O2/ml were added. Controls were incubated with anti-human antibody per-
oxidase only. After 1 h, the color development of the ELISA was quantified with
a CCD camera and an image-processing system using the image-processing
software package Optimas, version 6.5 (Media Cybernetics, Silver Spring, Md.).
Epitope alignment. The minimal binding region of the CR57 epitope was
aligned using glycoprotein amino acid sequences of the 229 rabies virus isolates
(for GenBank accession numbers, see supplementary material).
RESULTS
Rabies virus-neutralizing activity of human monoclonal an-
tibodies. Heavy- and light-chain sequences of the antibodies
SOJA, SOJB, and SO57 were cloned into our human IgG1
expression vector pcDNA3002. The antibodies, designated
CRJA, CRJB, and CR57, were produced in PER.C6 cells and
purified by affinity chromatography. The CRJB antibody was
originally of IgG3 format but was converted into an IgG1
molecule, because IgG1 molecules have a longer half-life than
IgG3 molecules. To establish the neutralizing activity of these
MAbs, the antibodies were tested in a modified RFFIT using
CVS-11 rabies virus (Table 1). The neutralizing activities of
CR57 and CRJB were higher than previously reported for the
TABLE 1. Neutralizing potencies of anti-rabies virus antibodies
Rhabdoviral systema PER.C6
IgG Potency (IU/mg) IgG Potency (IU/mg)
SO57 2,200 CR57 3,800
SOJB 240 CRJB 620
SOJA 30 CRJA 0.5
a See reference 25.
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antibodies produced using a rhabdoviral vector (25). In con-
trast, CRJA had such a low potency (0.5 IU/mg) that it was
excluded from further experiments.
Competition between rabies virus-neutralizing MAbs. To
investigate whether the antibodies CR57 and CRJB compete
with each other for binding to rabies virus glycoprotein, we
performed a set of competition experiments using either an
ELISA (fixed antigen conformation) or flow cytometry (native
antigen conformation) format. Analysis of competition in an
ELISA format on immobilized glycoprotein showed that the
negative control antibody, CR2428, did not block the binding
of either biotinylated antibody CR57bio or CRJBbio (Fig. 1A).
In contrast, when CR57bio and CRJBbio were coincubated
with their unlabeled counterpart IgGs, the binding of the
former was completely eliminated, thereby serving as an inter-
nal positive control. Both CR57 and CRJB also blocked bind-
ing of CRJBbio and CR57bio, respectively, indicating that the
two antibodies compete for binding to rabies virus glycopro-
tein. These experiments were also performed on immobilized
inactivated rabies virus (Pitman-Moore strain), and identical
results were obtained (data not shown).
Antibody competition was next studied by a flow cytometry-
based assay using rabies virus glycoprotein-expressing cells. In
this format, the glycoprotein is expressed on the cell surface
and can still undergo conformational changes, thereby mim-
icking more closely the natural situation on the virion. Figure
1B confirms that the binding of either CR57bio or CRJBbio is
blocked by the unlabeled CRJB or CR57, respectively, whereas
the negative control antibody CR2428 did not interfere with
binding.
Identification of a novel rabies virus-neutralizing epitope. In
contrast to the conformational epitope that is recognized by
CRJB, the SO57 MAb has been reported to react with dena-
tured rabies glycoprotein on Western blotting, suggesting in-
teraction with a linear epitope (8). To identify the region of the
glycoprotein that is recognized by CR57, a PEPSCAN-ELISA
was performed. Binding of the antibody to 15-mer linear pep-
tides (overlapping by 14 amino acids) spanning the extracellu-
lar domain of the mature protein was determined (data not
shown). CR57 recognized linear peptides in the region SLKG
ACKLKLCGVLGLRLMDGTW (aa 218 to 240). To further
identify the core amino acids within the binding region of
CR57, an 8-mer peptide PEPSCAN-ELISA was performed
(Fig. 2A). CR57 showed reactivity with three peptides:
KLKLCGVL, LKLCGVLG, and KLCGVLGL. This demon-
strates a minimal binding region, KLCGVL (aa 226 to 231),
within the rabies virus glycoprotein. Subsequently, we per-
formed an alanine replacement scan through the LKLCGVLG
peptide to identify the residues within the core peptide that are
critical for binding of the CR57 antibody. Figure 2B shows that
FIG. 1. CR57 and CRJB compete for binding to glycoprotein. Sat-
urating amounts of unlabeled IgG (indicated on x axes) were allowed
to bind to (A) immobilized glycoprotein or (B) glycoprotein expressing
cells before addition of biotinylated competitor IgG CR57bio (filled
bars) or CRJBbio (open bars). Binding is expressed as the percentage
of the binding (ELISA signal or mean fluorescence intensity) of the
biotinylated antibody alone.
FIG. 2. CR57 recognizes a linear epitope on rabies virus glycopro-
tein. (A) CR57 was tested using an 8-mer peptide PEPSCAN-ELISA
in a region of the rabies virus glycoprotein ectodomain identified using
overlapping 15-mer peptides. (B) Alanine replacement scan through
the core 8-mer peptide containing the minimal binding region as iden-
tified in panel A. Relative ELISA signals are shown for each peptide.
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the lysine (K) as well as the central CGV triplet are key resi-
dues within the minimal binding region for CR57 recognition
(K-CGV-).
Generation and characterization of escape viruses. To fur-
ther define and/or confirm the critical residues on the rabies
virus glycoprotein that are, through conformational changes,
directly or indirectly involved in binding of CR57 and CRJB,
we generated a number of antibody-resistant escape viruses
using both CR57 and CRJB, designated E57 and EJB escape
viruses hereafter. A total of six distinct escape viruses were
isolated for each antibody. Cross-neutralization of the E57 and
EJB escape viruses by CRJB and CR57, respectively, was ex-
amined by determination of the neutralization index (NI) for
the escape viruses. Each virus was grown in the absence and
presence of either selecting or nonselecting antibody. Subse-
quently, the virus titers were determined and used to calculate
the NI as described in Materials and Methods (Table 2). None
of the E57 viruses were neutralized by CR57, and two viruses
(E57A2 and E57B2) were also not neutralized by CRJB. In
contrast, EJB viruses were not covered by either CRJB or
CR57. This suggested that the epitopes recognized by CR57
and CRJB overlap. The glycoprotein-encoding genes from the
escape viruses were analyzed by direct sequencing of cDNA
that was obtained from infected NA cells. DNA sequence
analysis revealed several mutations in the glycoprotein gene
(Fig. 3, Table 3). Overall, four unique escape viruses for CR57
and two unique escape viruses for CRJB were isolated based
on glycoprotein amino acid sequence. The mutations K226E,
K226N, and G229E observed in the E57 viruses were located in
the CR57 minimal binding region (aa 226 to 231), as was
identified in the PEPSCAN-ELISA (Fig. 2). Moreover, the
mutations exactly coincided with the key amino acids within
the core peptide identified through the alanine replacement
scan. As expected, the introduction of the mutations observed
in the E57 viruses into the core wild-type 8-mer peptide elim-
inated binding of the CR57 MAb (data not shown). EJB vi-
ruses also harbored mutations (G229E and L231P) in the
CR57 minimal binding region, thereby confirming the compe-
tition results described above. In addition, all EJB viruses also
had an extra mutation at position 182 (N182D). This further
suggests that the mutation in position 182 and in the region 229
to 231 destabilizes the conformational epitope recognized by
CRJB.
Conservation of the novel epitope within rabies viruses. We
subsequently aligned the CR57 minimal binding region of gly-
coprotein sequences of 229 genotype 1 rabies virus isolates to
assess the conservation of the epitope (Table 4). The sample
set contained human isolates, bat isolates, and isolates from
canines or from domestic animals most likely bitten by rabid
canines. Frequency analysis of the amino acids at each position
within the minimal binding region revealed that the critical
residues constituting the epitope were highly conserved. The
lysine at position one was conserved in 99.6% of the isolates,
while in only 1 out of 229 isolates a conservative K-to-R mu-
tation was observed. Positions two and three (L and C, respec-
FIG. 3. Amino acid sequences of the E57 and EJB escape viruses.
Escape viruses were generated, amplified, and characterized as de-
scribed in Materials and Methods. (A) E57 escape virus glycoprotein
sequences. (B) EJB escape virus glycoprotein sequences. The relevant
amino acids harboring the mutations of each escape virus are depicted.
Boxed amino acids indicate the identified minimal binding region
required for CR57 recognition.
TABLE 2. Neutralization index of wild-type CVS-11
and escape virusesa
Virus NI (CR57) NI (CRJB) Escape of virus
CVS-11 6.8 6.8
E57A2 0.8 0 CR57  CRJB
E57A3 0.1 3.1 CR57
E57B1 0 2.8 CR57
E57B2 0 2.1 CR57  CRJB
E57B3 0 4.1 CR57
E57C3 0.8 3.9 CR57
EJB2B 0.2 0.1 CRJB  CR57
EJB2C 0 0.4 CRJB  CR57
EJB2D 0 0.1 CRJB  CR57
EJB2E 0 0.1 CRJB  CR57
EJB2F 0 0 CRJB  CR57
EJB3F 0.5 0.2 CRJB  CR57
a Neutralization index (NI) is shown as the log10 value for each antibody. NI
 2.5 was considered escape.
TABLE 3. Characterization of E57 and EJB escape virusesa
Virus Amino acid no. Amino acid change Codon change
E57A2 229 G to E GGA to GAA
E57A3 20 H to Q CAC to CAA
226 K to E AAG to GAG
E57B1, E57B3 226 K to E AAG to GAG
E57B2, E57C3 226 K to N AAG to AAT
EJB2B, 2C, 2F 182 N to D AAT to GAT
229 G to E GGA to GAA
231 L to P CTT to CCT
EJB2D, 2E, 3F 182 N to D AAT to GAT
231 L to P CTT to CCT
a Amino acid numbering is from the mature protein minus the signal peptide.
Wild-type CVS-11 sequence was determined in a similar fashion from the orig-
inal virus stock used to generate the escape viruses.
TABLE 4. Conservation of the CR57 minimal binding region
within rabies virusesa
K L C G V L
K (99.6%) L (100%) C (100%) G (98.7%) V (99.6%) L (70.7%)
R (0.4%) E (0.9%) I (0.4%) P (26.7%)
R (0.4%) S (2.6%)
a Percentage of occurrence of each amino acid is shown in parentheses for 229
rabies virus isolates.
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tively) were completely conserved. The glycine at position four
was conserved in 98.7% of the isolates, while in 3 out of 229
isolates mutations towards charged amino acids (R, 1 out of
229; E, 2 out of 229) were observed. The fifth position was also
conserved, with the exception of one isolate where a conser-
vative V-to-I mutation was observed. At the sixth position,
which is not a critical residue as determined by the alanine
replacement scan, significant heterogeneity is observed in the
street isolates: L in 70.7%, P in 26.7%, and S in 2.6% of the
strains, respectively. Alignment of the minimal binding region
with representative lyssaviruses belonging to genotypes 2 to 7
showed that within these genotypes the epitope is less well
conserved (Table 5). However, at the critical residues, geno-
types 4 to 7 have conserved amino acid changes, suggesting
potential recognition by CR57.
DISCUSSION
Present PEP treatment of rabies virus-infected people in-
volves the use of HRIG. Blood-derived products, like HRIG,
have potential health risks normally associated with those
products. Also, HRIG can display batch-to-batch variation and
may be limited in availability in case of sudden mass exposure
(5, 6). An alternative to HRIG would be to use human mono-
clonal antibodies produced according to industrial standards.
The concern regarding blood-derived products could thereby
be circumvented, and consistent batches of antibodies could be
produced in large quantities. Therefore, we initiated a study to
identify and characterize human MAbs to be included in such
a cocktail. We focused on the human MAbs previously de-
scribed by Prosniak et al. (25), which displayed potent neutral-
ization of several rabies virus strains.
For expression of the antibodies, we used the human cell line
PER.C6, which produces consistently high levels of antibody
and can easily be adapted for industrial use. This method
contrasts with that of the rhabdoviral antibody system (22),
which involves the error-prone rhabdoviral RNA polymerase
and is therefore less suitable as an industrial standard for the
production of a consistent, high-quality antibody. Reformat-
ting of the antibodies SOJA, SOJB, and SO57 into the PER.C6
expression system resulted in improved neutralizing potency of
the antibodies, with the exception of CRJA. We decided to
exclude CRJA from further experiments due to its low po-
tency. The low potency would result in exorbitant protein con-
tent if CRJA were to be used in a future cocktail of MAbs.
Therefore, CR57 and CRJB were further investigated.
Earlier data suggested that CR57 and CRJB show a distinct
pattern of coverage of different lyssavirus genotypes, which
may be based on qualitative or quantitative characteristics of
the respective MAbs (25). Competition experiments using both
immobilized rabies virus glycoprotein and glycoprotein ex-
pressed on cells showed that CR57 and CRJB recognize com-
peting, overlapping epitopes and cannot bind simultaneously
to the rabies virus glycoprotein (Fig. 1). CR57 was tested in a
PEPSCAN ELISA to determine the epitope and was shown to
recognize a linear peptide of the rabies virus glycoprotein (Fig.
2), which agreed with the finding that CR57 is able to bind to
reduced denatured rabies virus glycoprotein on Western blot-
ting. Detailed analysis of the binding region of CR57 revealed
a minimal binding region of 6 amino acids (KLCGVL, aa 226
to 231) critical for CR57 binding, with K-CGV as key residues
(Fig. 2). This finding was confirmed by analysis of the amino
acid sequences of the escape viruses generated with CR57.
Specific nonsilent point mutations (K226E, K226N, and
G229E) were detected in this minimal binding region (Fig. 3,
Table 3). This underlines the importance of these residues for
binding of CR57 to the rabies virus glycoprotein. Analysis of
the glycoprotein open reading frame of EJB viruses showed
point mutations in two different spots of the glycoprotein,
including mutations (G229E and L231P) within the minimal
binding region of CR57, indicating that amino acids within this
epitope are important for binding of CRJB to the rabies virus
glycoprotein. Furthermore, these data suggest that CRJB rec-
ognizes a nonlinear, conformational epitope that partially
overlaps with the minimal binding region of CR57. This is also
in agreement with the competition data described above.
Another goal of the escape virus studies was to mimic the
theoretical event of escape in vivo. Antibody escape viruses
could occur from naturally existing quasispecies present in the
virus inoculum as well as from antibody-dependent selection of
a neutralization-resistant variant as a consequence of a hu-
moral immune response against the virus. However, the latter
is not likely to occur, as was demonstrated by the observed
conservation of the antigenic sites on rabies virus glycoprotein
(2).
The antigenic structure of the rabies virus glycoprotein was
initially defined by Lafon et al. (18). The antigenic sites were
identified using a panel of mouse MAbs and their respective
MAb-resistant virus variants. Since then, the antigenic sites
have been mapped by identification of the amino acid muta-
tions in the glycoprotein of MAb-resistant variants (3, 24, 27).
The majority of rabies virus-neutralizing MAbs are directed
against antigenic site II (3), which is a discontinuous confor-
mational epitope comprising aa 34 to 42 and aa 198 to 200 (24).
Antigenic site III is a continuous conformational epitope at aa
330 to 338 and harbors two charged residues, K330 and R333,
that affect viral pathogenicity (7, 10, 27). The conformational
antigenic site I was defined by only one MAb, 509-6, located at
aa 231 (3, 18). Antigenic site IV is known to harbor overlap-
ping linear epitopes (4, 19, 23). Benmansour et al. (3) also
described the presence of a minor site located at position 342
to 343, which is distinct from antigenic site III despite its close
proximity.
Alignment of the CR57 epitope with the presently known
linear and conformational neutralizing epitopes on rabies virus
glycoprotein (Fig. 4) revealed that the CR57 epitope is located
in the same region as the conformational antigenic site I,
defined by the single MAb 509-6 (3, 10, 18). Competition
TABLE 5. Conservation of the CR57 minimal binding region
within Lyssaviruses
Lyssavirus Genotype Accession no. CR57 epitope
Rabies 1 J02293 KLCGVL
Mokola 2 AF298148 TLCGKP
Lagos bat 3 U17064 TLCGKP
Duvenhage 4 AF298146 RLCGIS
European Bat 1 5 AF298143 RLCGVP
European Bat 2 6 AF298145 KLCGIS
Australian Bat 7 AF006497 KLCGIS
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experiments described within this study revealed that CR57
and 509-6 competed for binding to ERA G in both ELISA and
fluorescence-activated cell sorting (data not shown). Interest-
ingly, neutralization of E57 escape viruses by 509-6 could be
demonstrated (data not shown), which agreed with earlier data
by Dietzschold et al. (8) showing neutralization of an SO57
escape variant by the 509-6 antibody. Coverage of 509-6 escape
viruses by CR57 could not be performed, as this escape virus
was not available. However, based on literature, it is expected
that CR57 does neutralize 509-6 escape viruses. CR57 neutral-
izes silver-haired bat rabies viruses (SHBRV) (25), which all
harbor a proline at position 231 (9, 21). This proline was
identical to the mutation L231P observed in the 509-6 escape
virus (3). Thus, SHBRV resemble the 509-6 escape virus with
respect to antigenic site I, suggesting that CR57 is capable of
neutralizing 509-6 escape viruses. Overall, antigenic site I
might be redefined as a region harboring both conformational
(MAbs CRJB and 509-6) and linear epitopes (CR57), as indi-
cated in Fig. 4.
We analyzed the glycoprotein sequence of a large set of
rabies virus isolates to assess the occurrence of quasispecies
that might have a mutation in the CR57 epitope. We observed
a high level of conservation within the CR57 epitope, which
was underlined by experiments showing that a panel of rabies
street viruses were all neutralized by CR57 in a standard
RFFIT (data not shown). This may be explained in part by the
presence of the central cysteine residue, which is structurally
involved in glycoprotein folding and is conserved among all
lyssaviruses (2). From the 229 analyzed naturally occurring
rabies virus isolates, only 3 isolates (AF346857, AF346861, and
U72050) contained nonconserved amino acid changes at key
residues within the epitope that would eliminate antibody
binding. Hence, approximately 99% of the rabies viruses that
can be encountered are predicted to be recognized by the
CR57 antibody.
In two bat virus isolates (AF346857 and AF346861), the
amino acid changes within the CR57 epitope were identical to
those observed in some of the EJB viruses (i.e., KLCEVP).
However, none of the 229 rabies virus isolates contained an
aspartic acid at position 182 of the mature glycoprotein, as was
observed in the EJB viruses. Apparently, such genotype 1 ra-
bies viruses do not exist in nature. In contrast, Mokola and
Lagos bat viruses do contain an aspartic acid at position 182 in
combination with a proline at position 231. In vitro analysis of
neutralizing activity of CR57 towards representative viruses of
genotypes 2 to 7 revealed that CR57 neutralizes genotypes 4 to
7 but not genotypes 2 and 3 (data not shown). The results
contradict earlier reports showing that CR57 only covers ge-
notype 1 viruses (8, 25). This might be explained by the muta-
tions we observed in the rhabdoviral pSPBN SO57 vectors
compared to the originally described MAb 57 sequence (16),
which potentially could result in altered antigen binding prop-
erties. Because the PER.C6-produced CR57 completely
matches the MAb 57-amino-acid sequence, the studies for-
mally cannot be compared because different MAbs were used.
In addition, it could be explained by the use of different virus
isolates as representatives of lyssavirus genotypes 2 to 7. Ap-
parently, mutation of the key residue K to R in genotypes 4 and
5 (Table 5) at position 1 of the minimal binding region of CR57
is tolerated as well as an isoleucine at position 5 (genotypes 4,
6, and 7). In contrast, changing key residues K to T at position
one and V to K at position five eliminates neutralization of
Mokola and Lagos bat viruses by CR57.
Our study showed that one of the most potent rabies virus-
neutralizing human MAbs recognizes a novel highly conserved
epitope on the glycoprotein of rabies viruses. This epitope was
shown to be linear and to contain four key residues for binding
of the antibody. All rabies virus variants escaping neutraliza-
tion by this MAb had nonsilent mutations in the key residues
of the epitope. The replacement of the wild-type amino acids
within a peptide that encompasses the minimal binding region
with those observed in the glycoprotein of the escape elimi-
nated antibody binding. The second antibody that we charac-
terized, CRJB, recognized a conformational epitope that par-
tially overlapped with the CR57 epitope, identifying a
neutralization epitope complex. Rabies virus mutants escaping
from CRJB completely escaped CR57 neutralization. These
results argue for the inclusion of only one of these two anti-
bodies in a cocktail product aimed at replacing HRIG.
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